Evoq Therapeutics, Inc.
Publicly observedAnn Arbor, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Ann Arbor | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Evoq Therapeutics, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | KC7MPKPPJDE7 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant19 Sept 2025Publicly observed
NIH SBIR/STTR award: NanoDiscs for Immune Modulation in Celiac Disease
USD 1,000,000.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant19 Sept 2025Publicly observed
NIH SBIR/STTR award: NanoDiscs for Immune Modulation in Celiac Disease
USD 1,050,000.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant15 Jul 2022Publicly observed
NIH SBIR/STTR award: Novel immunotherapy against MOG antibody disease
USD 988,943.00 · National Center for Advancing Translational Sciences · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.